Hypothyroidism and the presence of thyroid autoantibodies after SCT have been described earlier and are highly prevalent. 1 (Autoimmune) thyroid failure may be triggered by conditioning chemotherapy, TBI and graft-versus-host effect. 2 However, data on thyrotoxicosis or thyroid hormone excess are scarce and limited to case reports and case series. [3] [4] [5] [6] [7] Between February 2006 and August 2007, 3 of 85 patients (3.5%) receiving SCT in our unit developed clinical thyrotoxicosis. Patient characteristics and transplant modalities are shown in Table 1 . The respective numbers of patients receiving an allo-SCT without TBI, an allo-SCT with TBI, an autologous SCT without TBI and an autologous SCT with TBI within this time period were 20, 16, 47 and 2. Of the 36 patients receiving allo-SCT, 17 were treated with alemtuzumab (Campath-1H) and 19 without alemtuzumab. A significantly higher incidence of thyrotoxicosis occurred in patients also receiving TBI as compared with patients not treated with TBI (3/18 patients (17%) compared with 0/65 patients (0%), respectively (Po0.01, Fisher's exact test). There was no significant difference in the incidence of thyrotoxicosis between patients treated with alemtuzumab (Campath-1H) or not, either between auto-or allo-SCT.
In the three cases of clinical thyrotoxicosis, neither the donors nor the recipients had any history of thyroid disease. All patients were severely thyrotoxic with free T4 values ranging from 2.51 to 4.01 ng/100 ml (ref. value 0.90-1.7) and free T3 values ranging from 0.59 to 1.5 ng/100 ml (ref. value 0.18-0.46). No detectable levels of antibodies against TSH receptor, thyroglobulin or thyroid peroxidase were present in any patient. In all cases, an extremely low Tc66m pertechnate uptake was observed as well as a normal-sized nodule-free thyroid gland with low/normal vascularization on ultrasound examination. These findings resemble the findings observed in amiodarone-induced destructive thyroiditis. Administration of contrast has been ruled out, and none of the patients had been treated with drugs with known potential to induce thyroiditis (amiodarone, IFN-a).
As the clinical manifestations in patient nos. 1 and 2 were severe and the findings suggested a destructive thyroiditis, treatment with steroids was initiated, because steroids have been proven effective in amiodarone-induced destructive thyroiditis. 8, 9 Both patients were successfully treated with a short course of steroids (methylprednisolone 32 mg in tempering dose), resulting in a gradual decrease of thyroid hormone levels with the normalization of free T3 within, respectively, 10 and 8 days. Free T4 normalized within 16 and 20 days, respectively. Long-term follow-up (19 and 7 months, respectively) of these patients showed euthyroidism. Because the presentation of the thyrotoxicosis was less severe and a recently treated pulmonary aspergillosis was considered a contraindication for steroid therapy, patient no. 3 received a symptomatic treatment with a b-blocking agent. In this patient, there was a spontaneous evolution toward hypothyroidism.
Clinical hyperthyroidism after SCT can theoretically be due either to increased thyroid hormone synthesis or to destruction with the release of preformed thyroid hormone. Kami et al., in a prospective study monitoring thyroid function after SCT, observed 14% patients (8/57) to have a mild and mostly subclinical thyroid hormone excess (with free T4 and/or free T3 slightly elevated, 1-to 1.5-fold the upper limit of normal values). Overall 88% patients (7/8) had a variety of antibodies autoreactive to the thyroid. 6 In contrast, the patients in our retrospective cohort presented with clinical symptoms of thyrotoxicosis, confirmed by laboratory results. Free T4 and/or free T3 exceeded twofold the upper limit of normal values in all patients, and antibodies autoreactive to the thyroid gland were absent in all patients. These findings, together with a low uptake on thyroid scan and a normal appearance of the thyroid gland on ultrasound, point to thyrotoxicosis due to destructive thyroiditis with the release of preformed thyroid hormone. Several pathophysiological mechanisms have been described to contribute to the occurrence of destructive thyroiditis, namely irradiation, immune disturbances, drugs and infections. In our series, all three patients presenting with thyrotoxicosis had received TBI as part of the conditioning regimen. The interval between TBI and the onset of thyrotoxicosis was similar in these patients and could be compatible with a radiation-induced damage and the release of thyroid hormone causing thyrotoxicosis.
We report on a unique series of patients with clinical thyrotoxicosis after SCT, caused by destructive thyroiditis. TBI constitutes the major risk factor for this complication. Steroid treatment is very effective, but can be contraindicated in this specific patient group at high risk of opportunistic infections. Therefore, the optimal treatment strategy (wait and see using symptomatic b-blocking medication versus steroid treatment versus thyroidectomy in severe cases) has to be carefully established in each individual case. A prospective study examining the exact incidence (including the incidence of subclinical hyperthyroidism) and spontaneous evolution (in cases of clinical compensation) of post-SCT thyrotoxicosis is warranted. 
